Emergency Contraception

FSRH CEU response to European Medicines Agency recommendations regarding use of ulipristal acetate for management of uterine fibroids (February 2018)

01 February 2018

The European Medicines Agency (EMA) is currently reviewing the safety of use of Esmya® (ulipristal acetate) for management of uterine fibroids. This review follows reports of a very small number of cases worldwide of serious liver injury in women using Esmya. Until the review process is complete, temporary restrictions have been placed on commencing treatment with Esmya and guidelines for monitoring liver function in women already taking Esmya have been introduced. The EMA recommendations are available at: http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2018/02/news_detail_002902.jsp&mid=WC0b01ac058004d5c1

This document is up-to-date

FSRH CEU Statement: Response to Recent Publication Regarding Banh, et al - November 2020

17 November 2020

“The effects on ovarian activity of delaying versus immediately restarting combined oral contraception after missing three pills and taking ulipristal acetate 30 mg” The journal Contraception recently published a study investigating timing of combined oral contraceptive pill (COC) restart after missed pills and use of ulipristal acetate emergency contraception (UPA-EC). The FSRH CEU responds to this study and advises where guidance does—and does not—change.

This document is up-to-date

FSRH Guideline-related CPD Q&A: Emergency Contraception (March 2020)

03 December 2020

Log in to view this document. This document provides the answers to the CPD questions in the FSRH Guideline Sexual and Reproductive Healthcare: Emergency Contraception. 1 CPD credit can be claimed for answering the questions.

This document is up-to-date